ES2196527T3 - Derivados de 11,15-o-dialquilprostaglandina e, su procedimiento de produccion y medicamentos que incluyen estos como principio activo. - Google Patents

Derivados de 11,15-o-dialquilprostaglandina e, su procedimiento de produccion y medicamentos que incluyen estos como principio activo.

Info

Publication number
ES2196527T3
ES2196527T3 ES98901576T ES98901576T ES2196527T3 ES 2196527 T3 ES2196527 T3 ES 2196527T3 ES 98901576 T ES98901576 T ES 98901576T ES 98901576 T ES98901576 T ES 98901576T ES 2196527 T3 ES2196527 T3 ES 2196527T3
Authority
ES
Spain
Prior art keywords
derivatives
dialquilprostaglandina
medications
active principle
production procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98901576T
Other languages
English (en)
Inventor
Shuichi Ohuchida
Takayuki Maruyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2196527T3 publication Critical patent/ES2196527T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un derivado de 11, 15-O-dialquil prostaglandina E de fórmula (I) **fórmula** donde R es halógeno y un enlace o un doble enlace, o R es oxo y un doble enlace, y R1 y R2 son, cada uno independientemente, alquilo de C 1-4, R3 es alquilo de C1-10, alquenilo de C2-10, alquinilo de C2-10 o alquilo de C1-10, alquenilo de C2-10 o alquinilo de C2-10 sustituidos con fenilo, fenoxi, cicloalquilo de C3-7 o cicloalquiloxi de C3-7, donde el fenilo y el cicloalquilo pueden estar sustituidos con 1-3 grupos entre alquilo de C1- 4, alcoxi de C1-4, halógeno, trihalometilo o nitro, o las sales no tóxicas del mismo o clatratos de ciclodextrina del mismo,
ES98901576T 1997-02-10 1998-02-10 Derivados de 11,15-o-dialquilprostaglandina e, su procedimiento de produccion y medicamentos que incluyen estos como principio activo. Expired - Lifetime ES2196527T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4157197 1997-02-10

Publications (1)

Publication Number Publication Date
ES2196527T3 true ES2196527T3 (es) 2003-12-16

Family

ID=12612138

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98901576T Expired - Lifetime ES2196527T3 (es) 1997-02-10 1998-02-10 Derivados de 11,15-o-dialquilprostaglandina e, su procedimiento de produccion y medicamentos que incluyen estos como principio activo.

Country Status (10)

Country Link
US (1) US6288119B1 (es)
EP (1) EP1008588B1 (es)
JP (1) JP4044967B2 (es)
KR (1) KR20000070903A (es)
AT (1) ATE237587T1 (es)
DE (1) DE69813571T2 (es)
DK (1) DK1008588T3 (es)
ES (1) ES2196527T3 (es)
PT (1) PT1008588E (es)
WO (1) WO1998034916A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4834224B2 (ja) 1999-03-05 2011-12-14 デューク ユニバーシティ Ｃ１６不飽和ｆｐ−選択的プロスタグランジン類縁体
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
ES2584606T3 (es) 2002-10-10 2016-09-28 Ono Pharmaceutical Co., Ltd. Microesferas que comprenden ONO-1301
US20060128810A1 (en) * 2002-10-10 2006-06-15 Kyoto University Remedies for allergic diseases
WO2004074842A2 (en) * 2003-02-24 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep3 (prostaglandin e2 ep3)
WO2004089411A1 (ja) * 2003-04-03 2004-10-21 Ono Pharmaceutical Co., Ltd. 脊柱管狭窄症治療剤
EP2422814A1 (en) 2003-07-25 2012-02-29 Ono Pharmaceutical Co., Ltd. Remedy for cartilage-related diseases
US7833995B2 (en) * 2003-12-05 2010-11-16 Ono Pharmaceutical Co., Ltd. Blood flow promoters for cauda equina tissues
WO2005080367A1 (en) 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
MY145694A (en) * 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
MY144968A (en) * 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AU2006253356B2 (en) 2005-06-03 2011-12-01 Ono Pharmaceutical Co., Ltd. Agent for regeneration and/or protection of nerves
CA2618486A1 (en) 2005-08-09 2007-02-15 Asterand Uk Limited Ep2 receptor agonists
WO2007079078A1 (en) 2005-12-29 2007-07-12 Bayer Schering Pharma Aktiengesellschaft Diamine derivatives as inhibitors of leukotriene a4 hydrolase
AR063280A1 (es) 2006-10-12 2009-01-21 Xenon Pharmaceuticals Inc Uso de compuestos de espiro-oxindol como agentes terapeuticos
JP2010506853A (ja) * 2006-10-12 2010-03-04 ゼノン・ファーマシューティカルズ・インコーポレイテッド 疼痛などのナトリウムチャネル媒介性の疾患の処置のための、スピロ（［３，２−フロ］ピリジン−３，３’−インドール）−２’（１’ｈ）−オン誘導体および関連化合物
EP2220057A4 (en) 2007-11-14 2011-10-12 Cayman Chem Co PROSTAGLANDIN E1 AND E2 ANALOGUES FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS
CN105218565A (zh) 2008-10-17 2016-01-06 泽农医药公司 螺羟吲哚化合物及其作为治疗剂的用途
CA2741024A1 (en) * 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
CN102803239B (zh) 2009-06-10 2015-04-15 小野药品工业株式会社 具有膀胱排尿肌收缩活性和尿道括约肌舒张活性的化合物
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
MX2012004373A (es) * 2009-10-14 2012-06-28 Xenon Pharmaceuticals Inc Metodos sinteticos para compuestos espiro-oxoindol.
US20110086899A1 (en) * 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
CA2788440A1 (en) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
EA201491854A1 (ru) 2012-04-12 2015-03-31 Ксенон Фармасьютикалз Инк. Асимметрический синтез соединений спирооксиндола, полезных в качестве терапевтических средств
SG11201501451SA (en) 2012-08-31 2015-04-29 Ono Pharmaceutical Co Amine salt and crystals thereof
MX2015011677A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
EP2818484A1 (en) 2013-06-28 2014-12-31 Universitat Autònoma de Barcelona Synergistic combination of an anti-IgE antibody and an EP2 receptor agonist
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
US10100060B2 (en) 2016-06-16 2018-10-16 Xenon Pharmaceuticals Inc. Asymmetric synthesis of funapide
AU2017371353B2 (en) 2016-12-09 2022-02-03 Celltaxis, Llc Monamine and monoamine derivatives as inhibitors of leukotriene A4 hydrolase
CA3045887A1 (en) 2016-12-09 2018-06-14 Celtaxsys, Inc. Pendant amines and derivatives as inhibitors of leukotriene a4 hydrolase
AU2017371348B2 (en) 2016-12-09 2022-02-03 Celltaxis, Llc Inhibitors of leukotriene A4 hydrolase

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3835180A (en) * 1971-05-04 1974-09-10 Upjohn Co 15 alkoxy pge compounds
US3876690A (en) * 1973-05-11 1975-04-08 American Cyanamid Co 1-alkoxy-9-keto-prostenoic acid derivatives
GB1451798A (en) * 1973-08-02 1976-10-06 Ici Ltd Prostanoic acid derivatives
US4236027A (en) * 1977-10-17 1980-11-25 American Cyanamid Company Novel 11-alkoxy-9-keto (or hydroxy)-prostenoic acid derivatives and method for preparing same
JPS55115836A (en) * 1979-03-02 1980-09-06 Toray Ind Inc Preparation of methyl ether derivative
DE3510978A1 (de) * 1985-03-22 1986-09-25 Schering AG, Berlin und Bergkamen, 1000 Berlin Neue 9-halogenprostaglandine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JPH03101622A (ja) * 1989-09-11 1991-04-26 Green Cross Corp:The 肝炎予防治療剤

Also Published As

Publication number Publication date
EP1008588A4 (en) 2000-06-14
WO1998034916A1 (fr) 1998-08-13
KR20000070903A (ko) 2000-11-25
JP4044967B2 (ja) 2008-02-06
EP1008588B1 (en) 2003-04-16
DE69813571T2 (de) 2004-02-12
ATE237587T1 (de) 2003-05-15
DE69813571D1 (de) 2003-05-22
DK1008588T3 (da) 2003-07-28
PT1008588E (pt) 2003-09-30
EP1008588A1 (en) 2000-06-14
US6288119B1 (en) 2001-09-11

Similar Documents

Publication Publication Date Title
ES2196527T3 (es) Derivados de 11,15-o-dialquilprostaglandina e, su procedimiento de produccion y medicamentos que incluyen estos como principio activo.
BR0108893B1 (pt) composiÇço farmacÊutica contendo derivados de azetidina, composto derivado de azetidina, e, processo para a preparaÇço de compostos.
ATE260255T1 (de) 5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate
DE69615674D1 (de) Cyclobutan-derivate als inhibitoren der squalen-synthase und der protein farnesyltransferase
EA200200708A1 (ru) Производные бензазола и их применение в качестве модуляторов jnk
CY1106522T1 (el) Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
ES2243579T3 (es) Derivados de pirazolopirideno.
BRPI0108374B8 (pt) derivado de pirazina ou um sal deste e composição farmacêutica
BR0212787A (pt) Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica
ATE450499T1 (de) Durch enzyme spaltbare prodrugs von substituierten stickstoff-lost-derivaten
BR0210293A (pt) Uma preparação farmacêutica aquosa de cilostazol para utilização parenteral
BR0113590A (pt) 7-oxo-piridopirimidinas
BR0214842A (pt) Inibidores de integrase hiv
NO20025035D0 (no) Oksadiazolderivater som har anticancer-effekter
ATE337318T1 (de) Spiroverbindungen und diese als wirkstoff enthaltende adhäsionsmolekülinhibitoren
EP1329218A4 (en) PREVENTIVE / REMEDY AGENTS FOR PORTAL HYPERTENSION
BR9807330A (pt) Agentes inibidores do progresso de pterìgio e recorrência pós-operatória do mesmo
ATE218560T1 (de) Wasserlösliche ähnliche verbindungen und medicament-vorstufe von paclitaxel
DK1179342T3 (da) Medicinske sammensætninger til öjeblikkelig frigivelse ved oral anvendelse
ES2189080T3 (es) Derivados de creatina para el asma.
BR0110871A (pt) Derivados de sulfonamida
BR0011845A (pt) Complexo farmacêutico
BR0316876A (pt) Compostos de tiazol e composição farmacêutica compreendendo o mesmo
MA30179B1 (fr) Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique.